TICKERNERD
Menu
UPCUPCHealthcare · Drug Manufacturers - Specialty & Generic

UPC Stock Forecast: Universe Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$1.49

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 31 Oct 2026 — in the lower half.

Market cap
$7.5M
Ticker Nerd rank
28/ 100
Median analyst target
—
Analysts covering
—
Ticker Nerd rank

UPC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Universe Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
28/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
93
Growth
65
Quality
53
Momentum
52
Accruals
34
Issuance
28
Revisions
25
Value
16
Volatility
8

Size (93): Smaller than most of the companies we track.

Volatility (8): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

UPC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on UPC, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

UPC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

UPC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Universe Pharmaceuticals, Inc. (UPC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 79% of US stocks

Price / sales
0.4×

Cheaper than 83% of US stocks

Price / book
0.0×

Cheaper than 91% of US stocks

EV / EBITDA
11.6×

Cheaper than 32% of US stocks

Growth & margins
Revenue growth (YoY)
−1.3%

Higher than 26% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−16.6%

Higher than 22% of US stocks

Net margin
−10.9%

Higher than 19% of US stocks

Returns & dividend
Return on equity
−3.5%

Higher than 40% of US stocks

Return on assets
−1.7%

Higher than 38% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Universe Pharmaceuticals, Inc. (UPC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Universe Pharmaceuticals, Inc. has a market value of $7.5M and an enterprise value of −$18.6M.

  • Shares outstanding: 647,838.

  • Trailing P/E: −0.2×.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Universe Pharmaceuticals, Inc. employs 216 people.

market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

UPC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
UPCUniverse Pharmaceuticals, Inc.$7.5M28
INMInMed Pharmaceuticals, Inc.$8.8M41
SNOASonoma Pharmaceuticals, Inc.$5.3M35
GELSGelteq Ltd.$5.2M11
APUSApimeds Pharmaceuticals US, Inc.$4.5M10
BFRIBiofrontera, Inc.$13.0M68
YCBDcbdMD, Inc.$4.3M26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Universe Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest UPC news & analysis

Law Offices of Howard G. Smith Announces Investigation of Universe Pharmaceuticals INC.

Business Wire · 12 Oct 2026negative

Law Offices of Howard G. Smith said it is investigating potential claims against Universe Pharmaceuticals’ board of directors over whether the board breached fiduciary duties to shareholders. The firm invited UPC shareholders to contact it about participating or learning more.

Why it matters — UPC watchers may want to note the announced investigation into potential board fiduciary-duty claims.

The Law Offices of Frank R. Cruz Announces Investigation of Universe Pharmaceuticals INC.

Business Wire · 7 Oct 2026negative

The Law Offices of Frank R. Cruz said it is investigating potential claims against Universe Pharmaceuticals’ board of directors over whether the board breached fiduciary duties to shareholders. The notice invites shareholders who meet its stated share-purchase timing to discuss the matter.

Why it matters — The investigation concerns potential board duties to UPC shareholders, a matter relevant to investors following the company.

FAQ

Frequently asked questions about UPC stock

How does Ticker Nerd's model rank UPC?

As at 31 Oct 2026, Universe Pharmaceuticals, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).

What is the UPC stock forecast for 2030?

No analyst covering Universe Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UPC are extrapolating price history, which says nothing about the business.

What does Universe Pharmaceuticals, Inc. do?

Universe Pharmaceuticals Inc. Class A Ordinary Shares represents the equity of a China-based pharmaceutical company focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products.

What is the latest news on UPC?

The most recent item we track (Business Wire, 12 Oct 2026): "Law Offices of Howard G. Smith Announces Investigation of Universe Pharmaceuticals INC.". Law Offices of Howard G. Smith said it is investigating potential claims against Universe Pharmaceuticals’ board of directors over whether the board breached fiduciary duties to shareholders. The firm invited UPC shareholders to contact it about participating or learning more.

Company

About Universe Pharmaceuticals, Inc.

Universe Pharmaceuticals Inc. Class A Ordinary Shares represents the equity of a China-based pharmaceutical company focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. The company also offers biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements sourced from third-party manufacturers. Its product portfolio is designed to address common health conditions, including chronic ailments associated with aging, as well as cold and flu needs. Operating through its subsidiaries, Universe Pharmaceuticals serves customers in domestic and international markets and participates in the broader healthcare supply chain through production, distribution, and commercialization activities. Headquartered in Ji’an, Jiangxi, China, the company issues Class A ordinary shares as part of a dual-class share structure that is used in its corporate governance framework.

CEO Mr. Gang Lai · 216 employees · China · https://www.universe-pharmacy.com